Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled study of HB-101 CMV vaccine in CMV-seronegative kidney transplant recipients with CMV-seropositive living donors
2017-005047-32Phase 2Completed
- Sponsor
- HOOKIPA Pharma
- Start
- Jun 2018
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of HB-101 in cytomegalovirus disease (CMV) (3 arms), sponsored by HOOKIPA Pharma. Primary endpoints: Safety and reactogenicity of HB-101 and Efficacy in mitigating CMV DNAemia/viremia. Started Jun 2018; status: completed.
02
Drugs
HB-101
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2017-005047-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005047-32.